FIG 1.

Conceptual overview of translating utility of PHOM score. (A) Eight hundred three patients were in our database with imaging and clinical data for NSCLC treated primarily with SBRT. Two hundred forty-nine patients were excluded on the basis of their stage or treatment history. (B) The PHOM score is algorithmically calculated from a tumor segmented by a clinician. Note that this particular cross-section demonstrates a large tumor greater than stage II but was selected for visualization purposes. Only stage II tumors and below were selected for analysis. (C) We envision the PHOM score to have utility in prognostication, therapy selection, and risk stratification. NSCLC, non–small-cell lung cancer; PHOM, persistent homology; SBRT, stereotactic body radiation therapy.